Effect of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastasis
Prostate Cancer Patients With Bone MetastasisIt is the aim of this clinical study to evaluate the skeletal-related event rate and tolerability of zoledronic acid in patients with prostate cancer patients and bone metastases.
Efficacy and Safety of Zoledronic Acid in Patients With Bone Metastases of Any Solid Tumors or Multiple...
Treatment of Bone MetastasesZoledronic acid is a medication that slows the breakdown of bone. This study will assess the efficacy and safety of zoledronic acid in Chinese patients with multiple myeloma or other solid tumors with bone metastases.
Palliative Radiotherapy for Bone Metastases: Single Versus Multiple Fractions.
Bone MetastasesPainThe aim of the investigators study was to determine whether 8 Gy in a single fraction provides equivalent pain and narcotic relief compared to 30 Gy in 10 fractions for patients with painful bone metastases. The secondary objectives were to evaluate the frequency, duration of pain relief, narcotic relief, toxicity and the effect on quality of life measures for each of the two treatment arms.
Study of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With Intravenous (IV)...
Bone Metastases in Men With Hormone-Refractory Prostate CancerBone Metastases in Subjects With Advanced Breast Cancer1 moreThe purpose of this trial is to determine the effectiveness of AMG 162 in reducing urinary N-telopeptide in advanced cancer subjects with bone metastases.
Treatment of AIDS Vacuolar Myelopathy With Methionine
MyelopathyAIDS-Myelopathy1 moreThe purpose of this study is to determine whether methionine, an amino acid present in low doses in the normal diet, can improve myelopathy or stop its progression.
Feasibility Study of FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases
Bone MetastasisThis purpose of this study is to assess the feasibility of FLASH radiotherapy for the palliative treatment of painful bone metastases. FLASH radiotherapy is radiation treatment delivered at ultra-high dose rates compared to conventional radiation treatment.
Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS...
LeukemiaLeukemia9 moreTo characterize the safety and tolerability of 1) MBG453 as a single agent or in combination with PDR001 or 2) PDR001 and/or MBG453 in combination with decitabine or azacitidine in AML and intermediate or high- risk MDS patients, and to identify recommended doses for future studies.
Chemoradiation for Bone Metastasis
Breast CancerBone Metastasis1 morePain from bone metastases of breast cancer origin is treated with localized radiation. Modulating doses and schedules has shown little efficacy in improving results. Given the synergistic therapeutic effect reported for combined systemic chemotherapy with local radiation in anal, rectal, and head and neck malignancies, the investigators sought to evaluate the tolerability and efficacy of combined capecitabine and radiation for palliation of pain due to bone metastases from breast cancer Hypothesis: Given the hypothesis that regimens employing greater intensity radiation yield higher rates of pain relief, radiosensitization using a tumor targeted drug like Xeloda should improve the rate of complete pain relief as compared to radiosensitization with 5FU alone. Primary Objective: To determine the frequency and duration of pain relief and narcotic relief for the proposed regimen. Secondary Objective: To determine the toxicity of concurrent Capecitabine and radiotherapy in breast cancer patients with bone metastases.
Randomized Trial Comparing Conventional Radiotherapy With Stereotactic Radiotherapy in Patients...
Spinal MetastasesBone MetastasesThe purpose of the study is to investigate effectiveness of stereotactic body radiotherapy in patients with bone metastatic disease.
Hypofractionated Radiotherapy (16/2) for the Palliation of Complicated Bone Metastases in Patients...
Bone MetastasesLiterature has shown that hypofractionated radiotherapy regimens are efficacious in patients with complicated bone metastases and have a low potential for severe treatment-related toxicities. There is a clear need for hypofractionated schedules in the complicated bone metastases population, especially when considering the overarching aim of palliative radiotherapy and the clinical features of this patient population. As well, current research examining hypofractionated approaches in bone metastases patients with impending or pathologic fractures, neuropathic pain or accompanying soft tissue masses has been markedly scarce.